Insight Molecular Diagnostics Inc. (IMDX): auditor change — Oncocyte terminates Marcum as auditor, engages CBIZ CPAs for FY 2025

Insight Molecular Diagnostics Inc.

Terminated Marcum LLP effective April 11, 2025; engaged CBIZ CPAs P.C. on April 16, 2025 as auditor for FY 2025.
Change follows CBIZ CPAs' acquisition of Marcum's attest business effective November 1, 2024.
No disagreements or reportable events occurred during Marcum's tenure through April 11, 2025.
Marcum's reports for FY 2023 and 2024 were unqualified except for a going-concern note in 2023.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Insight Molecular Diagnostics Inc. dismissed Marcum LLP as its auditor.

Action: dismissal
Auditor: Marcum LLP
Successor: CBIZ CPAs P.C.

Exact text from the filing

On April 11, 2025, the Company terminated its relationship with Marcum as the Company’s independent registered public accounting firm

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Insight Molecular Diagnostics Inc. engaged CBIZ CPAs P.C. as its auditor.

Action: engagement
Auditor: CBIZ CPAs P.C.

Exact text from the filing

engaged CBIZ CPAs on April 16, 2025 as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025

View on SEC.gov

Browse all auditor changes →

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-005288

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.